PedAM
Pediatric Disease Annotations & Medicines
| brain ischemia | ||||
| Disease ID | 717 |
|---|---|
| Disease | brain ischemia |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:22) HP:0001695 | Cardiac arrest | 3 HP:0001297 | Cerebral vascular events | 3 HP:0001658 | Myocardial infarction | 2 HP:0002045 | Abnormally low body temperature | 2 HP:0001250 | Seizures | 2 HP:0003202 | Neurogenic muscle atrophy, especially in the lower limbs | 1 HP:0100543 | Cognitive deficits | 1 HP:0002633 | Vasculitis | 1 HP:0001907 | Thromboembolic disease | 1 HP:0002181 | Cerebral edema | 1 HP:0000618 | Blindness | 1 HP:0002170 | Intracranial hemorrhage | 1 HP:0002326 | TIA | 1 HP:0012531 | Pain | 1 HP:0000822 | Hypertension | 1 HP:0002171 | Cerebral gliosis | 1 HP:0002315 | Headaches | 1 HP:0002354 | Memory loss | 1 HP:0002140 | Ischemic stroke | 1 HP:0000726 | Dementia | 1 HP:0002500 | Leukoaraiosis | 1 HP:0000969 | Dropsy | 1 |
| Disease ID | 717 |
|---|---|
| Disease | brain ischemia |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:2) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs121912438 | 15350647 | 6647 | SOD1 | umls:C0007786 | BeFree | The superoxide dismutase1 (SOD1) G93A mutation does not promote neuronal injury after focal brain ischemia and optic nerve transection in mice. | 0.125991584 | 2004 | SOD1 | 21 | 31667299 | G | C |
| rs2108622 | 18574070 | 8529 | CYP4F2 | umls:C0007786 | GAD | [The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure.] | 0.004734064 | 2008 | CYP4F2 | 19 | 15879621 | C | T |
| rs386602118 | 24275008 | 627 | BDNF | umls:C0007786 | BeFree | Even though previous brain ischemia and WM lesion studies have been conducted and indicated that brain-derived neurotrophic factor (BDNF) might protect against neuronal cell death, the interaction between regional WMH volume and the BDNF Val66Met polymorphism on the cognitive performance of healthy elderly population remains unclear. | 0.120542884 | 2013 | NA | NA | NA | NA | NA |
| rs4233507 | 18574070 | 1579 | CYP4A11 | umls:C0007786 | GAD | [The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure.] | 0.002367032 | 2008 | NA | NA | NA | NA | NA |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:30) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0007786 | aminocaproic acid | D015119 | 60-32-2 | brain ischemia | MESH:D002545 | marker/mechanism | 20881558 | ||
| C0007786 | amphetamine | D000661 | 300-62-9 | brain ischemia | MESH:D002545 | marker/mechanism | 10765060 | ||
| C0007786 | baclofen | D001418 | 1134-47-0 | brain ischemia | MESH:D002545 | therapeutic | 9344559 | ||
| C0007786 | capsaicin | D002211 | 404-86-4 | brain ischemia | MESH:D002545 | therapeutic | 19211983 | ||
| C0007786 | carmustine | D002330 | 154-93-8 | brain ischemia | MESH:D002545 | marker/mechanism | 2836567 | ||
| C0007786 | cisplatin | D002945 | 15663-27-1 | brain ischemia | MESH:D002545 | marker/mechanism | 19293057 | ||
| C0007786 | enalapril | D004656 | 75847-73-3 | brain ischemia | MESH:D002545 | therapeutic | 10408248 | ||
| C0007786 | etomidate | D005045 | 33125-97-2 | brain ischemia | MESH:D002545 | marker/mechanism | 8559304 | ||
| C0007786 | felbamate | C047360 | 25451-15-4 | brain ischemia | MESH:D002545 | therapeutic | 8232947 | ||
| C0007786 | fluorouracil | D005472 | 51-21-8 | brain ischemia | MESH:D002545 | marker/mechanism | 19293057 | ||
| C0007786 | ifosfamide | D007069 | 3778-73-2 | brain ischemia | MESH:D002545 | marker/mechanism | 16174228 | ||
| C0007786 | indomethacin | D007213 | 53-86-1 | brain ischemia | MESH:D002545 | marker/mechanism | 16223416 | ||
| C0007786 | indomethacin | D007213 | 53-86-1 | brain ischemia | MESH:D002545 | therapeutic | 12524144 | ||
| C0007786 | isradipine | D017275 | 75695-93-1 | brain ischemia | MESH:D002545 | therapeutic | 11481148 | ||
| C0007786 | lidocaine | D008012 | 137-58-6 | brain ischemia | MESH:D002545 | therapeutic | 16192539 | ||
| C0007786 | morphine | D009020 | 57-27-2 | brain ischemia | MESH:D002545 | therapeutic | 19211983 | ||
| C0007786 | nimodipine | D009553 | 66085-59-4 | brain ischemia | MESH:D002545 | therapeutic | 15901647 | ||
| C0007786 | nitric oxide | D009569 | 10102-43-9 | brain ischemia | MESH:D002545 | marker/mechanism | 17564305 | ||
| C0007786 | norepinephrine | D009638 | 51-41-2 | brain ischemia | MESH:D002545 | marker/mechanism | 8099768 | ||
| C0007786 | phenylephrine | D010656 | 59-42-7 | brain ischemia | MESH:D002545 | therapeutic | 1614584 | ||
| C0007786 | pilocarpine | D010862 | 92-13-7 | brain ischemia | MESH:D002545 | marker/mechanism | 17971868 | ||
| C0007786 | rofecoxib | C116926 | - | brain ischemia | MESH:D002545 | marker/mechanism | 17393291 | ||
| C0007786 | rosiglitazone | C089730 | - | brain ischemia | MESH:D002545 | therapeutic | 17641846 | ||
| C0007786 | spermine | D013096 | 71-44-3 | brain ischemia | MESH:D002545 | marker/mechanism | 21307247 | ||
| C0007786 | tacrolimus | D016559 | 109581-93-3 | brain ischemia | MESH:D002545 | therapeutic | 17076660 | ||
| C0007786 | thiopental | D013874 | 76-75-5 | brain ischemia | MESH:D002545 | therapeutic | 10522791 | ||
| C0007786 | topiramate | C052342 | 97240-79-4 | brain ischemia | MESH:D002545 | therapeutic | 15128855 | ||
| C0007786 | tranexamic acid | D014148 | 1197-18-8 | brain ischemia | MESH:D002545 | marker/mechanism | 7000850 | ||
| C0007786 | vindesine | D014751 | 53643-48-4 | brain ischemia | MESH:D002545 | marker/mechanism | 2312856 | ||
| C0007786 | vitamin e | D014810 | 1406-18-4 | brain ischemia | MESH:D002545 | therapeutic | 21051774 | ||
FDA approved drug and dosage information(Total Drugs:13) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D002545 | vioxx | rofecoxib | 12.5MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D002545 | vioxx | rofecoxib | 12.5MG/5ML | SUSPENSION;ORAL | Discontinued | None | No | No |
| MESH:D002545 | vioxx | rofecoxib | 12.5MG | TABLET; ORAL | Discontinued | None | No | No |
| MESH:D002545 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D002545 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D002545 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D002545 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D002545 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D002545 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D002545 | topamax | topiramate | 100MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D002545 | topamax | topiramate | 15MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D002545 | inomax | nitric oxide | 100PPM Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | GAS;INHALATION | Discontinued | None | Yes | No |
| MESH:D002545 | lysteda | tranexamic acid | 650MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
FDA labeling changes(Total Drugs:13) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D002545 | 08/19/2004 | vioxx | rofecoxib | Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004. | Labeling | B | - | - | - | Merck | 02/18/2004 | FALSE' |
| MESH:D002545 | 08/19/2004 | vioxx | rofecoxib | Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004. | Labeling | B | - | - | - | Merck | 02/18/2004 | FALSE' |
| MESH:D002545 | 08/19/2004 | vioxx | rofecoxib | Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004. | Labeling | B | - | - | - | Merck | 02/18/2004 | FALSE' |
| MESH:D002545 | 12/22/2009 | topamax | topiramate | Migraine Prophylaxis | Safety and effectiveness for migraine prevention in pediatric patients have not been established Dose-related increased shift in serum creatinine in adolescent patients occurred in a clinical study Information added to Warnings and Precautions and Pediatric Use | Labeling | - | P | - | - | Ortho-McNeil-Janssen | - | FALSE' |
| MESH:D002545 | 12/22/2009 | topamax | topiramate | Migraine Prophylaxis | Safety and effectiveness for migraine prevention in pediatric patients have not been established Dose-related increased shift in serum creatinine in adolescent patients occurred in a clinical study Information added to Warnings and Precautions and Pediatric Use | Labeling | - | P | - | - | Ortho-McNeil-Janssen | - | FALSE' |
| MESH:D002545 | 12/22/2009 | topamax | topiramate | Adjunctive Treatment for Partial Onset Epilepsy in Infants and Toddlers 1 to 24 months | Effectiveness was not demonstrated as adjunctive therapy in a randomized, double-blind trial in infants/toddlers 1 to 24 months of age with refractory partial onset seizures Trials in infants/toddlers 1 to 24 months suggested some adverse reactions/toxicities not previously observed in older pediatric patients and adults; i.e, growth/length retardation, certain clinical laboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications. Information added to Warnings and Precautions and Pediatric Use | Labeling | B | - | - | - | Ortho-McNeil-Janssen | 07/24/2008 | FALSE' |
| MESH:D002545 | 12/22/2009 | topamax | topiramate | Adjunctive Treatment for Partial Onset Epilepsy in Infants and Toddlers 1 to 24 months | Effectiveness was not demonstrated as adjunctive therapy in a randomized, double-blind trial in infants/toddlers 1 to 24 months of age with refractory partial onset seizures Trials in infants/toddlers 1 to 24 months suggested some adverse reactions/toxicities not previously observed in older pediatric patients and adults; i.e, growth/length retardation, certain clinical laboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications. Information added to Warnings and Precautions and Pediatric Use | Labeling | B | - | - | - | Ortho-McNeil-Janssen | 07/24/2008 | FALSE' |
| MESH:D002545 | 07/15/2011 | topamax | topiramate | Monotherapy for partial onset or primary generalized tonic-clonic seizures | Expanded age range down to 2 years; previously approved for monotherapy for partial onset or primary generalized tonic-clonic seizures in patients10 years and older Information on weight based dosing in 2 to < 10 yearsPostmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |
| MESH:D002545 | 07/15/2011 | topamax | topiramate | Monotherapy for partial onset or primary generalized tonic-clonic seizures | Expanded age range down to 2 years; previously approved for monotherapy for partial onset or primary generalized tonic-clonic seizures in patients10 years and older Information on weight based dosing in 2 to < 10 yearsPostmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |
| MESH:D002545 | 03/28/2014 | topamax | topiramate | Prophylaxis of migraine headache | Approved for use in pediatric patients 12 years and older Safety and effectiveness in pediatric patients less than12 years have not been established for the prophylaxis treatment of migraine headache In the adolescent migraine trials (12 to 17 years), the most commonly observed adverse reactions were: paresthesia, upper respiratory tract infection, anorexia, and abdominal pain The most common cognitive adverse reaction in pooled double-blind studies in adolescent patients 12 to 17 years was difficulty with concentration/attention Markedly abnormally low serum bicarbonate values indicative of metabolic acidosis were reported in topiramate-treated adolescent migraine patients In topiramate-treated patients 12 to 17 years compared to placebo-treated patients, abnormally increased results were more frequent for creatinine, BUN, uric acid, chloride, ammonia, total protein, and platelets. Abnormally decreased results were observed with topiramate vs placebo treatment for phosphorus and bicarbonate Notable changes (increases and decreases) from baseline in systolic blood pressure, diastolic blood pressure, and pulse were observed more commonly in adolescents treated with topiramate compared to adolescents treated with placebo Information on dosing, adverse reactions, laboratory abnormalities, and clinical trials Postmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |
| MESH:D002545 | 03/28/2014 | topamax | topiramate | Prophylaxis of migraine headache | Approved for use in pediatric patients 12 years and older Safety and effectiveness in pediatric patients less than12 years have not been established for the prophylaxis treatment of migraine headache In the adolescent migraine trials (12 to 17 years), the most commonly observed adverse reactions were: paresthesia, upper respiratory tract infection, anorexia, and abdominal pain The most common cognitive adverse reaction in pooled double-blind studies in adolescent patients 12 to 17 years was difficulty with concentration/attention Markedly abnormally low serum bicarbonate values indicative of metabolic acidosis were reported in topiramate-treated adolescent migraine patients In topiramate-treated patients 12 to 17 years compared to placebo-treated patients, abnormally increased results were more frequent for creatinine, BUN, uric acid, chloride, ammonia, total protein, and platelets. Abnormally decreased results were observed with topiramate vs placebo treatment for phosphorus and bicarbonate Notable changes (increases and decreases) from baseline in systolic blood pressure, diastolic blood pressure, and pulse were observed more commonly in adolescents treated with topiramate compared to adolescents treated with placebo Information on dosing, adverse reactions, laboratory abnormalities, and clinical trials Postmarketing study | Labeling | - | P | - | - | Janssen | - | FALSE' |
| MESH:D002545 | 12/21/2010 | inomax | nitric oxide | Prevention of bronchopulmonary dysplasia | INOmax is not indicated for prevention of BPD in preterm neonates d 34 weeks gestational age.Efficacy for the prevention of BPD in preterm infants was not established in three ldouble-blind, placebo-controlled clinical trials in a total of 2,149 preterm infants Information on clinical trials, adverse reaction | Labeling | B | - | - | - | INO Therapeutics | 2/11/2010 | FALSE' |
| MESH:D002545 | 08/21/2013 | lysteda | tranexamic acid | Treatment of cyclic heavy menstrual bleeding | Indicated for women of reproductive age. It is not intended for use in premenarcheal girls Information on PK studyPostmarketing study | - | P | - | - | Ferring | - | FALSE' | - |